Uveitis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Summary of Updates

1.4. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of Uveitis

3.2. Uveitis SWOT Analysis

3.3. Progression of Uveitis

3.4. Diagnosis and Classification of Uveitis

4. Epidemiology

4.1. Diagnosed Incident Cases of Uveitis

4.2. Diagnosed Prevalent Cases of Uveitis

4.3. Age-Specific Trends in Diagnosed Prevalent Cases of Uveitis

4.4. Sex-Specific Diagnosed Prevalent Cases of Uveitis

4.5. Diagnosed Prevalent Cases od Uveitis by Etiology, Anatomical Site of Inflammation, and Severity

4.6. Sources and Methodology for Diagnosed Incident Cases of Uveitis

4.7. Sources and Methodology for Diagnosed Prevalent Cases of Uveitis

4.8. Sources and Methodology for Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation

4.9. Sources and Methodology for Diagnosed Prevalent Cases of Uveitis by Etiology

4.10. Sources and Methodology for Diagnosed Prevalent Cases of Uveitis by Severity

4.11. Sources and Methodology – Diagnosed Incident and Prevalent Cases of Uveitis

4.12. Sources and Methodology – Diagnosed Prevalent Cases of Uveitis by Anatomical Site

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Current Treatment Options

5.3. Current Treatment Options: Key Opinion Leader Perspective

5.4. Product Profile: Corticosteroid Eye Drops

5.5. Product Profile: Ocular Steroid Injections

5.6. Product Profile: Intraocular Corticosteroid Implants

5.7. Product Profile: Systemic Corticosteroids

5.8. Product Profile: Mydriatic Agents

5.9. Product Profile: Antimetabolites

5.10. Product Profile: Alkylating Agents

5.11. Product Profile: Calcineurin Inhibitors

5.12. Product Profile: Monoclonal Antibodies

5.13. Product Profile: Adrenocorticotropic Hormone Receptor Agonists

6. Unmet Needs and Opportunities

6.1. Unmet Needs in Uveitis

6.2. Improving Safety and Side-Effect Profile

6.3. Longer-Acting Therapy/Less Frequent Dosing

6.4. Drugs with Other Mechanisms of Action

6.5. Greater Awareness and Education of Physicians/Healthcare Providers

7. R&D Strategies

7.1. Trends in Clinical Trial Design for Uveitis

7.2. Trends in Deal-Making in Uveitis

8. Pipeline Assessment

8.1. Uveitis Pipeline Overview

8.2. Late-Stage Pipeline Agents for Uveitis

8.3. Product Profile: OCS-02

8.4. Product Profile: TRS-01

8.5. Product Profile: brepocitinib tosylate

8.6. Product Profile: Baricitinib

8.7. Product Profile: KIO-104

8.8. Product Profile: EBI-031

8.9. Uveitis Clinical Trials (Phase II/III) Overview

9. Market Outlook

9.1. Uveitis Market Outlook

9.2. Uveitis Market Forecast

9.3. Market Drivers and Barriers

10. Appendix

10.1. Primary Research – KOL Information

10.2. About the Authors

11. Contact Us

Table 1: Non-infectious Uveitis: Key Metrics in the 9MM

Table 2: SUN Working Group Anatomical Classification of Uveitis

Table 3: SUN Working Group Classification of Uveitis by Disease Onset and Duration

Table 4: Grading of Anterior Chamber Flare and Anterior Chamber Cells

Table 5: Grading of Vitreous Haze

Table 6: Autoimmune Uveitis and Ocular Complications

Table 7: Risk Factors and Comorbidities for Uveitis

Table 8: Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Etiology, and Severity

Table 9: Diagnosed Prevalent Cases of Uveitis by Laterality

Table 10: Treatment Guidelines for Uveitis in the 9MM

Table 11: Uveitis Disease Management – North America

Table 12: Uveitis Disease Management – 5EU

Table 13: Uveitis Disease Management – Japan and Australia

Table 14: Marketed Drugs for Uveitis Across the 9MM

Table 15: Comparison of Therapeutic Classes of Pipeline Drug Candidates for Non-infectious Uveitis, 2019-2029

Table 16: Phase I Pipeline Products in Development for Uveitis

Table 17: AbbVie’s Uveitis Portfolio Assessment, 2021

Table 18: Novartis’ Uveitis Portfolio Assessment, 2021

Table 19: Chugai’s Uveitis Portfolio Assessment, 2021

Table 20: Aciont’s Uveitis Portfolio Assessment, 2021

Table 21: Oculis’ Uveitis Portfolio Assessment, 2021

Table 22: Tarsius Pharma’s Uveitis Portfolio Assessment, 2021

Table 23: Enzo Biochem’s Uveitis Portfolio Assessment, 2021

Table 24: Santen’s Uveitis Portfolio Assessment, 2021

Table 25: Eyevensys’ Uveitis Portfolio Assessment, 2021

Table 26: Panoptes Pharma’s Uveitis Portfolio Assessment, 2021

Table 27: Uveitis Market – Global Drivers and Barriers, 2019-2029

Table 28: Key Events Impacting Sales for Uveitis in the US, 2019-2029

Table 29: Uveitis Market – Drivers and Barriers in the US, 2019-2029

Table 30: Key Events Impacting Sales for Uveitis in the 5EU, 2019-2029

Table 31: Uveitis Market – Drivers and Barriers in the 5EU, 2019-2029

Table 32: Key Events Impacting Sales for Uveitis in Japan, 2019-2029

Table 33: Uveitis Market – Drivers and Barriers in Japan, 2019-2029

Table 34: Key Events Impacting Sales for Uveitis in Canada, 2019-2029

Table 35: Uveitis Market – Drivers and Barriers in Canada, 2019-2029

Table 36: Key Events Impacting Sales for Uveitis in Australia, 2019-2029

Table 37: Uveitis Market – Drivers and Barriers in Australia, 2019-2029

Table 38: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global (9MM) Sales Forecast by Geographic Region for Uveitis in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in Uveitis During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Uveitis During the Forecast Period

Figure 4: Differentiation of Pro-inflammatory T-cells in Non-infectious Uveitis

Figure 5: 9MM, Diagnosed Incidence of Uveitis, Men and Women, Cases Per 100,000 Population, Ages ≥18 Years, 2019

Figure 6: 9MM, Diagnosed Prevalence of Uveitis, Men and Women, %, Ages ≥18 Years, 2019

Figure 7: 9MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of Uveitis

Figure 8: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation

Figure 9: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Etiology

Figure 10: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Severity

Figure 11: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Laterality

Figure 12: 9MM, Diagnosed Incident Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019

Figure 13: 9MM, Diagnosed Incident Cases of Uveitis by Age, N, Both Sexes, 2019

Figure 14: 9MM, Diagnosed Incident Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019

Figure 15: 9MM, Diagnosed Prevalent Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019

Figure 16: 9MM, Diagnosed Prevalent Cases of Uveitis by Age, N, Both Sexes, 2019

Figure 17: 9MM, Diagnosed Prevalent Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019

Figure 18: Unmet Needs and Opportunities in Uveitis

Figure 19: Snellen Chart Used to Measure Visual Acuity in Patients With Uveitis

Figure 20: Overview of the Development Pipeline in Uveitis

Figure 21: Key Ongoing Clinical Trials Involving Patients With Non-infectious Uveitis in the 9MM

Figure 22: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Uveitis During the Forecast Period

Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Ocular Application, Pred Forte

Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Systemic Treatment, Humira

Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Intraocular Preparation, Ozurdex

Figure 26: Analysis of the Company Portfolio Gap in Uveitis During the Forecast Period

Figure 27: Global (9MM) Sales Forecast by Geographic Region for Uveitis in 2019 and 2029

Figure 28: Sales of Corticosteroids for Uveitis in the 9MM, 2019 and 2029

Figure 29: Sales Forecast by Therapeutic Class for Uveitis in the 9MM, 2019 and 2029

Figure 30: Sales Forecast by Therapeutic Class for Uveitis in the US in 2019 and 2029

Figure 31: Sales Forecast by Therapeutic Class for Uveitis in the 5EU in 2019 and 2029

Figure 32: Sales Forecast by Therapeutic Class for Uveitis in Japan in 2019 and 2029

Figure 33: Sales Forecast by Therapeutic Class for Uveitis in Canada in 2019 and 2029

Figure 34: Sales Forecast by Therapeutic Class for Uveitis in Australia in 2019 and 2029